Jefferies analyst Brandon Couillard came out with a research report on Opko Health Inc. (NYSE:OPK) Friday, assuming coverage with a Hold rating and raising the price target to $11.00 (from $10.00), which represents a slight upside potential from current levels. Shares of Opko are trading slightly up (+0.38%) in pre-market trading.
Couillard noted, “OPK is emerging as a diversified hybrid medical products company focused on novel diagnostics (Dx) & drugs. The acquisition of BRLI adds a compelling distribution channel & commercial team for OPK’s unique blood-based prostate cancer risk test (4Kscore) & future new point-of-care launches, but timing of reimbursement milestones is unclear. With diagnostics accounting for >70% of revs thru 2020E, we are assuming coverage at Hold/$11 PT.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Brandon Couillard has a total average return of 14.5% and a 74.3% success rate. Couillard has a average return when recommending OPK, and is ranked #198 out of 3754 analysts.
Out of the 4 analysts polled by TipRanks, 2 rate Opko Health stock a Buy, while 2 rate the stock a Hold. With a return potential of 58.0%, the stock’s consensus target price stands at $16.67.